Virax Biolabs Group Ltd (VRAX) Noticias

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares PR...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form NT 20-F - Notification of inability to timely file Form 20-F

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral...

Virax Biolabs to Participate at ESCMID Global 2024

Virax Biolabs to Participate at ESCMID Global 2024 PR Newswire LONDON, April 16, 2024 LONDON, April 16, 2024...

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care...